|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **PCMN = 95** | **SMN = 92** | **Risk difference (95% CI)** | ***p*-value** |
| **Proportion of patients with at least one adverse event throughout 48 weeks** | n = 95, 62 (65.3%) | n = 92, 60 (65.2%) | -0.1% [-13.8%;+13.6%] | 0.988 |
| **Proportion of patients with at least one serious adverse event (SAE) throughout 48 weeks** | n = 95, 10 (10.5%) | n = 92, 11 (12.0%) | -1.3%[-10.2%;+7.7%] | 0.781 |

cART: combined antiretroviral therapy, DTG: dolutegravir, FTC: emtricitabine, PCM: patient-centered monitoring, SM: standard monitoring, ITT: intention-to-treat, SAE: serious adverse event, CI: confidence interval.

**S3 Table**: **Proportions of reported adverse events by monitoring arms. ITT analysis.**